SLU-PP-915 and SLU-PP-332 are both ERR agonists that can activate ERR α, ERR β, and ERR γ, promote mitochondrial production and fatty acid oxidation, and produce metabolic regulatory effects similar to those brought about by exercise. The main difference between the two lies in target preference and drug properties. SLU-PP-332 is an early lead compound with higher affinity for ERR α, but poor oral absorption. It is generally suitable for injection and is commonly used for laboratory control testing. SLU-PP-915 is a new generation molecule that has undergone structural optimization. With a different skeleton, it has good oral bioavailability, a more convenient administration method, stronger activation effect on ERR γ, and greater potential in the field of cardiac metabolism. The two have similar directions of action, both can enhance endurance and regulate fat metabolism, but their applicable scenarios are different.
Faithful Chemical offers both of these products. We provide high-quality service, ensuring that our products are of superior quality and meet international pharmaceutical standards. You can source products from Faithful Chemical with complete confidence.
SLU-PP-915 and SLU-PP-332 Description
Introduction to SLU-PP-915
SLU-PP-915 is an orally effective small molecule pan ERR agonist, CAS 2285432-92-8, molecular formula C17H13BFNO3S, molecular weight 341.16, developed by St. Louis University. It can balance the activation of three subtypes of ERR α, ERR β, and ERR γ, upregulate mitochondrial related genes such as PGC1 α, promote mitochondrial production, fatty acid oxidation, and oxidative phosphorylation, and has a motion simulation effect. Compared to SLU-PP-332, SLU-PP-915 has a different skeleton and its core advantage is good oral bioavailability. Oral administration can still be stable and effective, and it can also produce synergistic gains with exercise. It has outstanding activation of the ERR γ pathway and is commonly used for preclinical evaluation in areas such as heart failure, obesity, metabolic syndrome, and sarcopenia. SLU-PP-915 has good selectivity and almost no significant activation effect on estrogen receptor ER. Currently, it is only for scientific research purposes and cannot be used in humans.
Introduction to SLU-PP-332
SLU-PP-332 is a small molecule pan ERR agonist developed by St. Louis University, CAS：303760-60-3, Molecular formula C18H14N2O2, molecular weight 290.32. It can promote mitochondrial production, fatty acid oxidation, and has a motion simulation effect, which can enhance skeletal muscle endurance and improve glucose and lipid metabolism. SLU-PP-332 has poor oral bioavailability and is commonly used for intraperitoneal injection. It is suitable for cell and animal control experiments and is used for preclinical evaluation in obesity, metabolic syndrome, and sarcopenia. This molecule has no significant activation of the classical estrogen receptor ER, and compared to SLU-PP-915, it has a different skeleton and focuses more on the study of the ERR α pathway. SLU-PP-332 is only used as a research reagent and is strictly prohibited from being directly used on the human body.
Differences in the molecular characteristics of SLU-PP-332 and SLU-PP-915
Molecular characteristics of SLU-PP-915
SLU-PP-915 is a small molecule pan ERR agonist with oral activity. The molecular skeleton is a 2,5-disubstituted thienoamide structure with boronic acid groups, which differs significantly from the structure of SLU-PP-332. The boronic acid group enhances the metabolic stability of molecules in microsomes and is also the key to their good oral absorption ability. This molecule can bind to the ligand binding domains of ERR α, ERR β, and ERR γ, with balanced activity and relatively higher affinity for ERR γ. It hardly activates the traditional estrogen receptors ER α/ER β. After targeting, SLU-PP-915 recruits co activators, upregulates downstream genes such as PGC1 α, and promotes mitochondrial production and fatty acid oxidation. This molecule is only used for preclinical research and cannot be applied to the human body.
Molecular characteristics of SLU-PP-332
SLU-PP-332 is a small molecule pan ERR agonist with an acylhydrazone structure containing naphthalene groups, which differs significantly from the structure of SLU-PP-915. The planar naphthalene ring structure can form π - π stacking interactions with key amino acids in the ligand binding pocket. The target preference shows the strongest binding ability to ERR α, followed by ERR β and ERR γ. It hardly activates the traditional estrogen receptors ER α and ER β. After molecular binding to receptors, the active conformation of ERR receptors can be stabilized, co activating factors can be recruited, downstream gene expression such as PGC1 α can be increased, mitochondrial production and fatty acid oxidation can be promoted. The molecule has a fast metabolic clearance rate and poor oral bioavailability, and injection administration is mostly used in experiments. This molecule is only used for preclinical studies and cannot be used in the human body.
Global Market Description
In cross-border B2B procurement scenarios, experienced buyers in the fields of biotechnology and research and development pay close attention to the differentiated characteristics of SLU-PP-332 and SLU-PP-915, two pan-ERR agonists. They no longer only focus on whether these compounds can activate ERR subtypes and regulate mitochondrial metabolism. Buyers attach great importance to impurity control standards, batch consistency and pharmacokinetic differences of the two products to obtain stable and repeatable data in preclinical metabolic research and compound formulation trials. When R&D personnel select SLU-PP-332 or SLU-PP-915 for ERR pathway research, fatty acid oxidation assessment, mitochondrial biogenesis detection and pharmacological target validation, they need to consider not only their basic biological activity and subtype selectivity, but also core quality indicators and administration properties, to guarantee experimental stability and research credibility in cell assays, animal disease models and preclinical compound screening systems. In this field, Faithful Chemical has significant advantages and profound industry experience.
| Category | Details |
| Market trend up to 2026 | Global market for SLU-PP-332 and SLU-PP-915 research compounds keeps growing steadily with rising metabolism-related preclinical projects |
| Available product form | Research-grade powder for both SLU-PP-332 and SLU-PP-915 |
| Available product form | Most versatile and reliable research-grade format for direct comparison testing of the two ERR agonists |
| Applicable scenarios | In vitro ERR binding assays, in vivo animal model administration, preclinical metabolic pharmacological evaluation, laboratory formulation and dosing scheme optimization, side-by-side control studies |
Three Core Driving Forces
01
Rising research focus on metabolic disorders, sarcopenia and heart metabolism fuels demand for pan-ERR agonist research compounds
02
Preclinical screening projects require stable research powder with clear subtype preference and pharmacokinetic profiles to minimize experimental variation
03
Advances in mitochondrial energy metabolism research expand the application scope of SLU-PP-332 and SLU-PP-915
Faithful Chemica offers reasonable prices and excellent service. We ensure high product quality that meets international pharmaceutical standards, so you can purchase with confidence.
Purchasing Notes For SLU-PP-332 & SLU-PP-915
Buyers shall verify local import rules before purchasing SLU-PP-332 and SLU-PP-915. Both compounds are for laboratory research only, not for human use or clinical therapy.
Full documents including COA and MSDS should be ready for customs clearance. End-use is restricted to preclinical research; human administration and off-label application are forbidden.
heck batch specifications upon receipt. We offer batch traceability. Storage and handling must follow lab safety standards, and proper personal protection is required for ERR agonist substances.
Mechanism and Use
Mechanism Description
| SLU-PP-332 | SLU-PP-915 |
| SLU-PP-332 functions as a pan-ERR agonist, preferentially binding to the ligand-binding domain of ERRα to stabilize its active conformation. | SLU-PP-915 acts as an orally available pan-ERR agonist, binding to ERRα, ERRβ and ERRγ with balanced potency and showing relatively higher affinity for ERRγ. |
| It recruits coactivator complexes and upregulates PGC1α, triggering mitochondrial biogenesis and enhancing fatty acid oxidative metabolism. | It recruits coactivators and elevates the expression of PGC1α, stimulating mitochondrial biogenesis and boosting fatty acid oxidation. |
| It produces exercise-mimicking metabolic effects, with negligible activation on classic estrogen receptors ERα/ERβ. | It induces exercise-mimicking metabolic responses while having nearly no activating effect on conventional estrogen receptors ERα/ERβ. |
Use Description
| SLU-PP-332 | SLU-PP-915 |
| Used for ERRα-focused pathway research to explore the regulatory mechanism of estrogen-related receptor on energy metabolism. | Used for balanced pan-ERR pathway research, especially for exploring ERRγ-mediated cardiac and metabolic regulation. |
| Applied in preclinical animal models to evaluate effects on skeletal muscle endurance, lipid metabolism and metabolic disorders. | Applied in preclinical animal studies to assess oral efficacy on mitochondrial function, obesity and sarcopenia. |
| Served as a control compound for side-by-side comparison with other pan-ERR agonists such as SLU-PP-915 in pharmacological screening. | Used in pharmacological screening as an orally bioavailable comparator against injectable ERR agonists like SLU-PP-332. |
Questions Buyers Ask Before Placing A Bulk Order
Conclusion and References
Conclusion
SLU-PP-915 and SLU-PP-332 are both pan ERR agonists that can activate ERR receptors, upregulate PGC1 α, promote mitochondrial production and fatty acid oxidation, and produce motion simulation effects. They are only used for preclinical research and cannot be used in the human body. The core differences between the two are reflected in target preferences, drug characteristics, and applicable scenarios. SLU-PP-332 has a higher affinity for ERR α, but its oral bioavailability is low. It is generally administered by injection and is commonly used in control trials focusing on the ERR α pathway. SLU-PP-915 is an optimized molecule with outstanding affinity for ERR γ, balanced activation activity of various subtypes, and good oral absorption capacity. It is suitable for long-term animal experiments of oral administration and has advantages in cardiac metabolism related research. In screening experiments, the two are often paired as comparative tool compounds.
Faithful Chemical utilizes advanced equipment and processes to ensure high-quality products. Our SLU-PP-332 & SLU-PP-915 meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and preferred superior service make us the partner for medical institutions and researchers worldwide.
If you require SLU-PP-332 & SLU-PP-915 research or production
Please contact Faithful Chemical Click
Email: allen@faithfulbio.com
WhatsApp: +86 13137770562.
References
- Billon, C., Sitaula, S., Banerjee, S., Welch, R., Elgendy, B., Hegazy, L., Oh, T. G., Kazantzis, M., Griffett, K., & Burris, T. P. (2023). Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chemical Biology, 18(4), 756–771.
- Hampton, C. S., Sitaula, S., Billon, C., Haynes, K., Avdagic, A., Wanninayake, U., Adeyemi, C. M., Chatterjee, A., Griffett, K., Banerjee, S., Burris, S. L., Schoepke, E., Boehm, T., Bess, A., de Vera, I. M. S., Burris, T. P., & Walker, J. K. (2023). Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. European Journal of Medicinal Chemistry, 258, 115582.
- Billon, C., Appourchaux, K., Côté, I., & Burris, T. P. (2025). An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. Journal of Pharmacology and Experimental Therapeutics, 393(1), 103787.
- Xu, W., Billon, C., Li, H., Wilderman, A., Qi, L., Graves, A., Rideb, J. R. D. C., Zhao, Y., Hayes, M., Yu, K., Wynshaw-Boris, A., Burris, T. P., & Zhang, L. (2024). Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation, 149(3), 227–250.
- Sitaula, S., Billon, C., Griffett, K., & Burris, T. P. (2022). Pharmacological targeting of estrogen-related receptors to mimic the metabolic benefits of exercise. Pharmacological Reviews, 74(3), 682–705.